MeSH D050171 - dyslipidemias
Favorite
Competitive Landscape
Events Timeline
Commercial
Clinical Trials
Competitive landscape
Events Timeline
Commercial
Company Name | Drug Name | Trade Name | Patent Expires | Approval Date | Revenue | Period |
|---|---|---|---|---|---|---|
| Novartis | Inclisiran | Leqvio | 2020-12-09 | $284 M | Q2/21-Q2/24 | |
| Sanofi | Alirocumab | Praluent | 2015-09-23 | |||
| Merck & Co | Laropiprant, Nicotinic acid | Pelzont | 2008-07-03 | |||
| Laropiprant, Nicotinic acid | Tredaptive | 2008-07-03 | ||||
| Laropiprant, Nicotinic acid | Trevaclyn | 2008-07-03 | ||||
| Daiichi Pharmaceutical | Bempedoic acid | Nilemdo | 2020-04-01 | |||
| Bempedoic acid, Ezetimibe | Nustendi | 2020-03-27 | ||||
| Amarin Corporation | Icosapent ethyl | Vazkepa | 2021-03-26 | |||
| Amgen | Evolocumab | Repatha | 2015-07-17 | $2,222 M | Y2024 | |
| Laboratoires SMB | Fenofibrate, Pravastatin | Pravafenix | 2011-04-14 | |||
| Viatris | Fenofibrate, Simvastatin | Cholib | 2013-08-26 |
Clinical Trials
Historical Success Rate
Phase 1
72%21/29
Phase 2
65%20/31
Phase 3
59%37/63
Approved: 10Overall Success rate: 27%
All Clinical Trials
Therapeutic Areas:
All
Classification:
All
Approval:
All
Status:
All
Phases:
All
Company name | Phase 1 | Phase 2 | Phase 3 | Phase 4 | Drug Name |
|---|---|---|---|---|---|
© 2020-2025 Collaborative Drug Discovery Inc. (CDD) | Terms of Use